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School of Biological Sciences, Faculty of Science, University of Hong Kong, Pokfulam, Hong Konga; Food, Nutrition and Health Program, Faculty of Land and Food
Systems, University of British Columbia, Vancouver, British Columbia, Canadab; Maryland Institute for Applied Environmental Health, School of Public Health, University of
Maryland, College Park, Maryland, USAc; Institute of Public Health and Clinical Nutrition, University of Eastern Finland, Kuopio, Finlandd
Defensins are small antimicrobial peptides (AMPs) that play an important role in the innate immune system of mammals. Since
the effect of mycotoxin contamination of food and feed on the secretion of intestinal AMPs is poorly understood, the aim of this
study was to elucidate the individual and combined effects of four common Fusarium toxins, deoxynivalenol (DON), nivalenol
(NIV), zearalenone (ZEA), and fumonisin B1 (FB1), on the mRNA expression, protein secretion, and corresponding antimicro-
bial effects of porcine-defensins 1 and 2 (pBD-1 and pBD-2) using a porcine jejunal epithelial cell line, IPEC-J2. In general,
upregulation of pBD-1 and pBD-2mRNA expression occurred following exposure to Fusarium toxins, individually and in mix-
tures (P< 0.05). However, no significant increase in secreted pBD-1 and pBD-2 protein levels was observed, as measured by en-
zyme-linked immunosorbent assay (ELISA). Supernatants from IPEC-J2 cells exposed to toxins, singly or in combination, how-
ever, possessed significantly less antimicrobial activity against Escherichia coli than untreated supernatants. When single toxins
and two-toxin combinations were assessed, toxicity effects were shown to be nonadditive (including synergism, potentiation,
and antagonism), suggesting interactive toxin effects when cells are exposed to mycotoxin combinations. The results show that
Fusarium toxins, individually and in mixtures, activate distinct antimicrobial defense mechanisms possessing the potential to
alter the intestinal microbiota through diminished antimicrobial effects. Moreover, by evaluating toxin mixtures, this improved
understanding of toxin effects will enable more effective risk assessments for commonmycotoxin combinations observed in
contaminated food and feed.
Antimicrobial peptides (AMPs) are effector molecules of in-nate immunity with direct antimicrobial activity (1). AMPs
can also be mediators of inflammation, influencing a variety of
processes, such as proliferation, adaptive immune system regula-
tion, wound repair, cytokine and histamine release, chemotaxis,
and protease and antiprotease balance (1–8). To date, hundreds of
AMPs identified from vertebrates, invertebrates, plants, and fungi
have been characterized, with sequence data deposited in the An-
timicrobial Sequences Database (AMSDb), which is publically
available (http://www.bbcm.univ.trieste.it/~tossi/amsdb.html) (9).
One of themajor AMP subclasses includes the-defensin fam-
ily. Themembers are mainly expressed in epithelial cells of organs
exposed to the external environment, such as the skin, gastroin-
testinal tract, and respiratory tract (10). Dynamic regulation of
-defensins has been shown in various models of gastrointestinal
illnesses and inflammation. For example, Campylobacter jejuni
was shown to induce bactericidal human -defensins 2 and 3
(hBD-2 and hBD-3) in intestinal epithelial cells (IECs) (11). Re-
ports have also demonstrated that Salmonella infection differen-
tially affected the expression of porcine -defensin 1 (pBD-1) and
pBD-2 mRNA transcript levels in porcine ileum and jejunum ep-
ithelial cells (10, 12).
Fusarium spp. are commonly recovered from cereals grown in
temperate areas of America, Europe, and Asia (13). Fusarium tox-
ins elicit a wide spectrum of toxic effects, including the capacity to
modify normal immune functions in both humans and animals
(14). The most important Fusarium toxins potentially affecting
mammalian health are zearalenone (ZEA), fumonisin B1 (FB1),
and trichothecenes, such as deoxynivalenol (DON) and nivalenol
(NIV). In crops and associated food products, the presence of
multiple mycotoxin types is commonly observed around the
world, making Fusarium toxins a serious public health concern.
However, investigations on the combined effects of mycotoxins
observed in the food supply are scarce. The few studies performed
have been based on endpoints that include inhibition of protein
and DNA synthesis, DNA methylation and fragmentation, cell
viability, and proliferation (15–20). However, the combined ef-
fects of mycotoxins on intestinal immunity are currently poorly
understood. Previous experiments have shown that exposure to
several mycotoxins may increase susceptibility to experimental or
natural mucosal infections by inducing bacterial translocation
and colonization across the intestinal epithelium (21, 22), but no
data are available examining the role mycotoxin combinations
may play in intestinal infections. Reports have been done demon-
strating that the antimicrobial activity of AMPs, such as -de-
fensins, may be associated with bacterial populations in the intes-
tine, which naturally present a barrier limiting undesirable gut
mucosal infections (23–25). Accordingly, we hypothesized that a
mixture of naturally cooccurring Fusarium toxins that can be ob-
served in food exert significant effects on the synthesis and secre-
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tion of AMPs compared to their effects as individual toxins. Such
effects could have a significant influence on microbial survival in
the gut. This study used a porcine intestinal epithelial cell line,
IPEC-J2 (25), to investigate the individual and interactive effects
of DON, NIV, ZEA, and FB1 on the mRNA expression and secre-
tion of pBD-1 and pBD-2 and examined antimicrobial effects ob-
served in toxin-exposed cell supernatants.
MATERIALS AND METHODS
Chemicals and reagents. All mycotoxins (DON, NIV, ZEA, and FB1),
dimethyl sulfoxide (DMSO), phosphate-buffered saline (PBS), Luria-
Bertani (LB) broth, and agar were obtained from Sigma Chemical
Company (St. Louis, MO). Dulbecco’s modified Eagle medium
(DMEM)–Ham’s F-12 (1:1) and fetal bovine serum (FBS) were pro-
vided by Gibco-Life Technology (Eggenstein, Germany). RNAiso Plus
was purchased from TaKaRa (Dalin, China). SuperScript III First-Strand
Synthesis SuperMix was supplied by Invitrogen Life Technologies (Carls-
bad, CA). Fast SYBR green master mix was obtained from Applied Bio-
systems (Foster City, CA). Commercial enzyme-linked immunosorbent
assay (ELISA) kits for pBD-1 and pBD-2 were purchased from Uscn Life
Science Inc. (Wuhan, China).
Cell line and culture conditions. IPEC-J2 is a nontransformed intes-
tinal cell line originally derived from the jejunums of neonatal, unsuckled
piglets (26) and was a kind gift of Per Torp Sangild (Department of Hu-
man Nutrition/Clinical Nutrition, Faculty of Life Science, University of
Copenhagen, Copenhagen, Denmark). Cells (passages 80 to 92) were
maintained in DMEM–Ham’s F-12 (1:1) containing high glucose (4.5
g/liter) supplemented with 10% FBS and incubated at 37°C in an atmo-
sphere of 5% CO2-95% air mixture. All cells were screened for myco-
plasma contamination prior to use (Lonza, Basel, Switzerland).
Preliminary mycotoxin concentration response experiment. Fusar-
ium toxin (DON, NIV, ZEA, and FB1) concentrations were optimized
previously by 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium
bromide (MTT) assay (L. Y. M. Wan, P. C. Turner, and E. El-Nezami,
submitted for publication). Identified concentrations for toxins, individ-
ually and in combination, were used to examine the impact on mRNA
expression, secreted-protein levels, and associated antimicrobial effects,
as described below.
Identification of mycotoxin combination treatments. To minimize
the number of possible toxin combinations (i.e., all possible combinations
for every concentration of the respective toxin), an inscribed central com-
posite designwas used (27). It incorporated a fractional factorial approach
with four factors (i.e., DON, NIV, ZEA, and FB1) and has been used
similarly previously (Wan et al. submitted). Through this approach, the
number of toxin combination treatments was reduced from 44 to 16. The
design matrix is presented in Table 1.
qPCR. IPEC-J2 cells were seeded at a density of 5 105 CFU/well in
6-well culture plates (Costar, Corning, NY) and allowed to adhere for 24
h. Typically, confluence was achieved after 3 to 4 days, with media being
replaced three times weekly; for all experiments, cells were used within 14
days from seeding (26). The cells were washed with PBS and treated with
Fusarium toxins in serum-freemedium for 48 h. Total RNAwas extracted
using RNAiso Plus according to the manufacturer’s instructions. RNA
was resuspended in 30 l of nuclease-free water and stored at 80°C.
RNA concentrations were measured using a NanoDrop ND-1000 Spec-
trophotometer (Nano-DropTechnologies,Wilmington,DE). Prior to use
in quantitative PCR (qPCR), RNA quality was determined by ensuring a
value of 1.8 for the A260/A280 ratio. cDNA was prepared from 1 g of
total RNA using SuperScript III First-Strand Synthesis SuperMix accord-
ing to the manufacturer’s instructions. qPCR was performed to quantify
mRNA transcript levels for pBD-1 and pBD-2 relative to the expression of
the glyceraldehyde-3-phosphate dehydrogenase (GAPDH) endogenous
housekeeping control gene. All samples were run on a StepOnePlus Real-
Time PCR system (Applied Biosystems, Foster City, CA) using 1 l of
cDNA and Fast SYBR green master mix, with final primer concentrations
of 0.5 Mper primer in a final volume of 20 l. Porcine specific cytokine
primers (Table 2) were generated from published GenBank sequences
using Primer Express software (Applied Biosystems). Samples were cen-
trifuged briefly and thermocycled using the default fast program (40 cy-
cles of 95°C for 3 s, 60°C for 30 s). Relative changes in gene expression
levels of pBD-1 and pBD-2 in cultured jejunal enterocytes resulting from
mycotoxin treatments were normalized against GAPDH using the
2CTmethod as described previously (28). Experiments were repeated
four times independently, with each treatment performed in triplicate.
ELISA analysis of pBD-1 and pBD-2. Protein levels of pBD-1 and
pBD-2 in cell supernatants were analyzed using a commercial ELISA kit
for pBD-1 and pBD-2 according to the manufacturer’s instructions. All
samples were run in duplicate, with experiments repeated three times
independently for each treatment.
Analysis of antibacterial activity.To examine the antibacterial effects
of toxin treatments on exposed IPEC-J2 cells, a clinical Escherichia coli
strain, ATCC 25922, kindly provided by W. C. Yam, Department of Mi-
crobiology, University of Hong Kong, was employed. In short, all tests
were performed with E. coli grown at 37°C in LB broth to an optical
density at 600 nm of 0.4. Cells were centrifuged at 2,060  g (Beckman
TABLE 1 Design matrix for four Fusarium toxins
Treatment
combination no.
DON (0.5
or 2 M)
NIV (0.5 or
2 M)
ZEA (10 or
40 M)
FB1 (20 or
40 M)
1 0a 0 0 0
2 1b 0 0 0
3 0 1 0 0
4 0 0 1 0
5 0 0 0 1
6 1 1 0 0
7 1 0 1 0
8 1 0 0 1
9 0 1 1 0
10 0 1 0 1
11 0 0 1 1
12 1 1 1 0
13 1 1 0 1
14 1 0 1 1
15 0 1 1 1
16 1 1 1 1
a 1, mycotoxin treatment.
b 0, no mycotoxin treatment.
TABLE 2 Primer sequences for quantification of pBD-1, pBD-2, and GAPDH by qPCR
Primer set
Product
length (bpa)
Primer sequence (5=–3=)
Accession no.Forward Reverse
pBD-1 141 CTCCTCCTTGTATTCCTCCT GGTGCCGATCTGTTTCAT NM_213838
pBD-2 148 GACTGTCTGCCTCCTCTC GGTCCCTTCAATCTGTTG NM_214442
GAPDH 120 ATGGTGAAGGTC GGAGTG GTAGTGGAGGTCAATGAAGG NM_001206359
a bp, base pairs.
Wan et al.
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Coulter, Fullerton, CA; GS-6R centrifuge) for 15 min and resuspended in
sterile phosphate-buffered saline (PBS) at a final concentration of 1.0 
107 CFU/ml. A 0.5-ml aliquot was mixed with 0.5 ml of supernatant ob-
tained from IPEC-J2 cells exposed or unexposed to the respective toxin
treatments. Following incubation for 2 h at 37°C with shaking (200 rpm),
serial dilutions were plated on LB agar, with CFU counted after 18 h at
37°C. Relative changes in CFU following treatment were calculated as
(CFU after mycotoxin-treated cell supernatant incubation)/(CFU after
control cell supernatant incubation).
Statistical analyses. Results of qPCR and antimicrobial effects were
expressed as the mean standard error of the mean (SEM) of four indi-
vidual experiments. All data analyses were performed using the SPSS sta-
tistical package (SPSS version 20.0 for Windows; SPSS Inc., Chicago, IL).
Data were first evaluated for normality with the Shapiro-Wilk and Lev-
ene’s variance homogeneity test. The data were not normally distributed
for pBD-1 and pBD-2 mRNA and protein levels but were normally dis-
tributed forCFU counts.One-way analysis of variance (ANOVA)with the
Kruskal-Wallis test, followed by the Mann-Whitney U test, was used to
identify significant differences for nonparametric data. One-way ANOVA
withDunnett’smultiple-comparison test was used for analyzing paramet-
ric data. Differences were considered to be statistically significant when P
values were less than 0.05. Differences in pBD-1 and pBD-2 protein levels
for three independent experiments were analyzed using a scatter plot.
Univariate analyses of variance were performed to determine if there
were any associations between different toxin treatments and bacterial
survival. Effects with P values of less than 0.05 at the 95% confidence
interval were regarded as significant, suggesting potential interactive ef-
fects (either synergistic or less than additive) of different Fusarium toxins
detected in the bacterial-survival assay, whereas effects with P values of
0.05 at the 95% confidence interval were considered nonsignificant. A
lack of interaction indicates the effects are additive (i.e., combined effects
would be the sum of their individual effects) (29). Correlations between
pBD-1 and pBD-2 gene expression, supernatant protein levels, and anti-
bacterial effects of supernatants of IPEC-J2 cells treatedwith cytotoxic and
noncytotoxic concentrations of DON, NIV, ZEA, and FB1, individually
and inmixtures, were assessed by Pearson’s (parametric) and Spearman’s
(nonparametric) correlations.
RESULTS
Individual and combined effects of mycotoxins on pBD-1 and
pBD-2 mRNA expression in IPEC-J2 epithelial cells. Levels of
mRNA expression of pBD-1 and pBD-2 in IPEC-J2 cells following
exposure to DON, NIV, ZEA, or FB1 are presented in Fig. 1. Rel-
ative levels of pBD-1were upregulated in IPEC-J2 cells upon treat-
ment with cytotoxic concentrations (expressed as toxin and con-
centration in M, e.g., DON 2 represents DON at 2 M) of
Fusarium toxins alone (DON 2, NIV 2, or ZEA 40) or in any
combination of DON 2, NIV 2, ZEA 40, and FB1 40, except NIV
2-ZEA 40. When cells were treated with noncytotoxic concentra-
tions of DON 0.5, NIV 0.5, ZEA 10, and FB1 20, relative levels of
pBD-1 mRNA were significantly (P  0.05) downregulated in
FIG 1 Relative abundances of pBD-1 and pBD-2 mRNAs from porcine IPEC-J2 cells isolated 48 h following treatment, individually or in combination, with
cytotoxic (A) and noncytotoxic (B) concentrations of DON, NIV, ZEA, and FB1. The results are expressed as means (standard errors of the mean [SEM]; n	
4) relative to the control; *, **, and ***, P 0.05, 0.01, and 0.001, respectively, compared to the control.
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DON 0.5 andNIV 0.5 alone and inmixtures of DON 0.5-NIV 0.5,
DON 0.5-ZEA 10, NIV 0.5-ZEA 10, NIV 0.5-FB1 20, DON 0.5-
NIV 0.5-ZEA 10, NIV 0.5-ZEA 10-FB1 20, and DON 0.5-NIV
0.5-ZEA 10-FB1 20 but were upregulated in ZEA 10 and FB1 20
alone and mixtures of DON 0.5-FB1 20, ZEA 10-FB1 20, DON
0.5-NIV 0.5-FB1 20, and DON 0.5-ZEA 10-FB1 20.
Similarly, pBD-2 mRNA expression was significantly (P 
0.05) upregulated in most of the cytotoxic treatment groups, ex-
cept for DON 2-NIV 2-ZEA 40 treatment. However, when cells
were treated with noncytotoxic concentrations of DON 0.5, NIV
0.5, ZEA10, andFB1 20, significant upregulation of pBD-2mRNA
expression was observed only in ZEA 10 and FB1 20 alone and in
mixtures of DON 0.5-NIV 0.5, NIV 0.5-ZEA 10, NIV 0.5-FB1 20,
ZEA 10-FB1 20, DON 0.5-NIV 0.5-ZEA 10, DON 0.5-NIV 0.5-
FB1 20, DON 0.5-ZEA 10-FB1 20, NIV 0.5-ZEA 10-FB1 20, and
DON 0.5-NIV 0.5-ZEA 10-FB1 20.
ELISAanalysis of pBD-1andpBD-2protein levels in IPEC-J2
cell culture supernatants. Since the qPCR data revealed changes
in mRNA expression of pBD-1 and pBD-2 following exposure to
cytotoxic and noncytotoxic concentrations of DON, NIV, ZEA,
and FB1, individually and in mixtures, cell supernatants were also
measured for their respective protein levels by ELISA. Scatter plots
showing the effects of mycotoxins, individually and in mixtures,
on pBD-1 and pBD-2 secretion levels are presented in Fig. 2. Dif-
ferences were not statistically significant for any treatment.
Antibacterial activities of cell culture supernatants. The an-
tibacterial activities of pBD-1 and pBD-2 in cell culture superna-
tants were evaluated by plate counting. When IPEC-J2 cells were
treated with cytotoxic concentrations of DON 2, NIV 2, ZEA 40,
and FB1 40, concentrations of E. coli were significantly increased
(P 0.05) in DON 2, NIV 2, and FB1 40 alone and in mixtures of
DON 2-NIV 2, NIV 2-FB1 40, ZEA 40-FB1 40, DON 2-NIV
2-ZEA 40, DON 2-NIV 2-FB1 40, DON 2-ZEA 40-FB1 40, NIV
2-ZEA 40-FB1 40, and DON 2-NIV 2-ZEA 40-FB1 40 (Fig. 3A).
However, when cells were treated with noncytotoxic concentra-
tions of DON 0.5, NIV 0.5, ZEA 10, and FB1 20, significant in-
creases in the concentrations of E. coliwere observed only for NIV
alone, NIV 0.5-ZEA 10, DON 0.5-NIV 0.5-FB1 20, NIV 0.5-ZEA
10-FB1 20, and DON 0.5-NIV 0.5-ZEA 10-FB1 20 (Fig. 3B). Such
increases in E. coli concentrations demonstrated that treated cell
supernatants possessed reduced antibacterial activity.
In order to determine if there were any interactions among
DON, NIV, ZEA, and FB1 affecting E. coli survival, univariate
ANOVA was conducted (Table 3). ANOVA provides a powerful
statistical tool for tests involving multiple factors and their inter-
actions (30). The results reveal nonadditive interactions in mix-
tures of NIV 2-FB1 40 (F1,151	 31.383; P 0.001), DON 2-NIV
2-FB1 40 (F1,151 	 17.788; P  0.001), and DON 2-NIV 2-ZEA
40-FB1 40 (F1,151	 12.432; P	 0.001) (Table 3). No interactions
FIG 2 Scatter plots illustrating the cytotoxic (A) and noncytotoxic (B) effects of DON, NIV, ZEA, and FB1, individually and in mixtures, on pBD-1 and pBD-2
levels in cell supernatants as analyzed by ELISA. Means are indicated by the horizontal lines (n	 3).
Wan et al.
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were observed for noncytotoxic concentrations of DON, NIV,
ZEA, and FB1 (data not shown).
Correlations among pBD-1 and pBD-2 mRNA expression,
protein levels, and antibacterial activity.Upon exposure to cyto-
toxic concentrations ofDON,NIV, ZEA, and FB1, significant pos-
itive correlations were observed between pBD-1 and pBD-2
mRNA expression levels (P  0.001) as determined by qPCR.
Significant negative correlations were revealed between pBD-1
and pBD-2 protein levels (P 0.001). The antibacterial activities
of the cell culture supernatants correlated significantly (P 	
0.031) with pBD-2 mRNA expression. However, when cells were
treated with noncytotoxic concentrations, the only significant
correlationwas between pBD-1mRNAexpression and pBD-2 lev-
els (P	 0.038), though the reasons for this are not clear (Table 4).
DISCUSSION
This is the first study to demonstrate the individual and combined
effects of four commonly occurring Fusarium toxins, DON, NIV,
ZEA, and FB1, on the mRNA expression and protein secretion of
AMPs pBD-1 and pBD-2. Following treatment with most toxins,
mRNA expression was significantly affected for both genes,
though cell supernatant levels of pBD-1 and pBD-2 were not sig-
nificantly changed. In this study, the expression of pBD-1 and
pBD-2 was shown to be low and is similar to what has been re-
ported for other cells (10, 24, 31). It has previously been suggested
that this basal level of expression may reflect a potential for
upregulation of these defensins upon bacterial infection, and
upregulation of these defensins has been reported following Sal-
monella infection (10, 24).
pBD-1 is a well-known porcine homologue of hBD-2 (32).
Zhang et al. (8) and Elahi et al. (33) previously showed pBD-1 to
be constitutively expressed in different tissues (8). However, in-
duction of pBD-1mRNA expressionmay also be stimulated upon
exposure to food contaminants or enteric pathogens (10, 33, 34)
and is in line with our data, which show pBD-1mRNA expression
was upregulated following exposure to DON,NIV, ZEA, and FB1,
individually and inmixtures. Elevated expression of pBD-1 in, for
example, IECs may play a potential role in surveillance andmain-
tenance of a homeostatic state of microflora on the mucosal epi-
thelium and may be significant in preventing the development or
progression of diseases (33, 35, 36).
pBD-2, on the other hand, is a recently discovered and de-
scribed porcine defensin found in the intestines of pig species and
is speculated to be the porcine orthologue of hBD-1 (24, 37). Re-
sults show that mRNA expression of pBD-2 was upregulated in
IPEC-J2 cells following exposure to DON, NIV, ZEA, and FB1,
individually and in mixtures. It has been reported that upregula-
tion of defensins contributes to the early response to bacterial
infections, tissue injury, and inflammation (23). Any disturbance
of defensin production may lead to the disruption of microbial
homeostasis, potentially contributing to chronic enteric diseases,
such as Crohn’s disease (11, 38) and inflammatory bowel disease
(39).
To date, regulation of pBD-1 and pBD-2 levels has been de-
scribed at the transcriptional level (10, 12, 24, 31), with little data
on posttranscriptional regulation available (40). Thus, we inves-
tigated the protein levels of pBD-1 and pBD-2 present in cell su-
pernatants and compared them with our transcriptional data ob-
tained by qPCR. For both proteins, no significant increases in
FIG 3 Antibacterial activities of IPEC-J2 cell culture supernatants as determined by numbers of CFU following exposure to cytotoxic (A) and noncytotoxic (B)
concentrations of DON, NIV, ZEA, and FB1, individually and in mixtures. The number of E. coliCFU in the control was set at 1. The results are expressed as the
relative change in the CFU count (SEM) compared to the control (n	 4). *, **, and ***, P 0.05, 0.01, and 0.001, respectively, compared to the control.
TABLE 3 Results of univariate analyses of multiple-Fusarium-toxin
exposure (cytotoxic) on IPEC-J2 cells as analyzed by surviving CFU
Toxin combination
CFU
F value P valuea
DON-NIV 0.506 0.478
DON-ZEA 0.939 0.334
DON-FB1 0.977 0.325
NIV-ZEA 0.029 0.865
NIV-FB1 31.383 <0.001
ZEA-FB1 1.874 0.173
DON-NIV-ZEA 3.415 0.067
DON-NIV-FB1 17.788 <0.001
DON-ZEA-FB1 0.35 0.555
NIV-ZEA-FB1 1.235 0.268
DON-NIV-ZEA-FB1 12.432 0.001
a Boldface indicates P 0.05.
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protein levels were observed under our experimental conditions,
which were inconsistent with the significant changes observed
with mRNA levels. Discrepancies between mRNA expression,
protein abundance, and biological effects have been reported in
previous studies (41–43). These differences may be explained, at
least partly, by posttranscriptional or posttranslational regulatory
mechanisms linked to defensin molecule secretion and are likely
influenced by protein degradation pathways (44), though this re-
mains to be shown. Moreover, differences between defensin
mRNA and protein secretion may also reveal issues associated
with detection thresholds for either mRNA or protein, or secre-
tion of the proteins. Despite advances in the technologies formea-
suring protein abundance in recent decades, the experimental
techniques for protein identification and quantification still lag
considerably behind the highly sensitive methods available for
quantifying mRNA transcript levels (45). However, while mRNA
expression values are useful in various applications, such as clas-
sification, identification, and prediction of drug-induced toxici-
ties or cancers (46, 47), the results are correlative rather than caus-
ative. It is generally recognized that changes in protein levels, even
when subtle (i.e., less thanwhat is deemed statistically significant),
may have significant biological effects, and this is currently an area
in which analytical techniques with increased sensitivity are re-
quired (45).
The results of the antibacterial assay indicate the relevance of
defensin expression in gastrointestinal immunity (1). Interest-
ingly, exposure of cells tomycotoxins, individually and/or in com-
bination, resulted in significant reductions in antibacterial activity
against E. coli, though significant changes in protein levels of
pBD-1 andpBD-2were not observed. It is possible thatmycotoxin
exposure leads to the production of other antimicrobial metabo-
lites or proteins in cell supernatants thatmay indirectly contribute
to the observed results. Nevertheless, although no significant in-
creases in protein levels for either pBD-1 or pBD-2 were observed,
subtle changes may still contribute to and/or reflect dysregulated
immunity in the IECs (48), which is supported by the apparent
and significant reductions in antibacterial effects associated with
toxin-treated cells reported in the current study.
Additionally, in order to determine whether changes inmRNA
expression, protein secretion, and/or antibacterial activity may be
attributed to cytotoxic effects, noncytotoxic concentrations of
DON (0.5 M), NIV (0.5 M), ZEA (10 M), and FB1 (20 M)
were investigated (Wan et al., submitted). The results showed that
noncytotoxic concentrations of DON, NIV, ZEA, and FB1 alone
or in combination also affected mRNA expression and protein
secretion of pBD-1 and pBD-2, as well as antibacterial activity.
However, significant upregulation of pBD-1 and pBD-2 mRNA
expression and reductions in antibacterial effects were primarily
observed in toxinmixtures found to cause cytotoxicity in theMTT
assay (Wan et al., submitted). Therefore, it is possible that cyto-
toxic effectsmay contribute to the antibacterial activity of IPEC-J2
cells. However, it is currently not clear whether this may have
occurred, and if so, what the mechanism(s) may be. Further stud-
ies are required to characterize the effects of individual and com-
bined Fusarium toxins on the regulation of pBD-1 and pBD-2
protein levels and the associated antibacterial activities.
There is no information in the literature regarding the com-
bined effect of Fusarium toxins on antibacterial activity in vitro. In
this study, significant interactions between treatments in the pres-
ent analysis would indicate that the addition of more than one
mycotoxin has a nonadditive effect, whereas an observed lack of
interaction would indicate that effects were additive (29). The
results showed that additive effects were noted inmost of the toxin
mixtures, leading to increases in bacterial survival compared with
single treatments of Fusarium toxin. A similar phenomenon was
reported byGroten et al. (49) and Tajima et al. (51), who observed
additive effects on the inhibition of DNA synthesis when L929
fibroblasts were exposed tomultiple Fusarium toxins (DON,NIV,
T-2 toxin, ZEA, and FB1), though some synergistic interactions
were also reported (49, 51). Additive effectsmay occur when there
is cooccurrence of more than one mycotoxin causing toxicity
through the same mechanism of action (52). In our study, inter-
active effects, which have not been reported previously, were ob-
served inmixtures containingNIV and FB1, though the reason for
such interaction remains unknown. This may indicate that these
commonly occurring Fusarium toxins, when combined, may in-
teract with each other so that the magnitude of the resulting toxic
effects generated may be potentiated or reduced by actions of
other toxins (51). Synergistic actions may occur when mycotoxin
mixtures act at different stages of the same toxicity pathway or
when the presence of one mycotoxin increases the absorption or
decreases themetabolic degradation of another (52). Antagonism,
TABLE 4 Correlations among pBD-1 and pBD-2 mRNA expression, protein levels, and antibacterial activity for cytotoxic and noncytotoxic
concentrations of Fusarium toxins
Parameter at Fusarium
toxin concn:
Valuea
pBD-1 pBD-2
mRNA Secretion mRNA Secretion
Cytotoxic
pBD-1 secretion 0.041 (0.787)
pBD-2 mRNA 0.344 (<0.001) 0.130 (0.465)
pBD-2 secretion 0.003 (0.986) 0.666 (<0.001) 0.104 (0. 557)
CFU 0.015 (0.859) 0.138 (0.395) 0.186 (0.031) 0.086 (0.597)
Noncytotoxic
pBD-1 secretion 0.191 (0.204)
pBD-2 mRNA 0.003 (0.969) 0.006 (0. 972)
pBD-2 secretion 0.304 (0.038) 0.289 (0.051) 0.198 (0.202)
CFU 0.088 (0.259) 0.054 (0.720) 0.054 (0.489) 0.052 (0.728)
a Values are expressed as correlation coefficients, with P values in parentheses (boldface indicates P 0.05).
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on the other hand,may occurwhenmycotoxins competewith one
another for the same target/receptor site (53). However, the pres-
ent results with multiple Fusarium toxins suggest that Fusarium
toxins alonemay not predict their effects in natural environments,
where combinations of toxins are frequently observed, meaning
that investigations of commonly observed toxinmixtures are nec-
essary and would enable more accurate and effective risk assess-
ments (54). To understand the nature of these interactive effects, a
molecular-level understanding of mycotoxin-mycotoxin interac-
tion is required in the future in order to develop more effective
detoxification and remediation strategies aimed at understanding
mycotoxin impacts on animal and human health (55).
In summary, gene expression, protein secretion for pBD-1 and
pBD-2, and the consequent antimicrobial impact of cell superna-
tants of IPEC-J2 cells following exposure to DON, NIV, ZEA, and
FB1, individually and in mixtures, were determined. A conse-
quent induction of mRNA for both defensins was observed,
though this significant transcriptional induction did not correlate
with significant changes in the respective secreted protein levels.
Regardless, toxin exposure resulted in reduced antibacterial ef-
fects observed in cell supernatants, suggesting exposure to myco-
toxins may contribute to microbiome changes in the gastrointes-
tinal environment. Based on our data, Fusarium toxins, either
alone or in combination, potentially activate distinct antimicro-
bial defense mechanisms, which may alter the intestinal microbi-
ota, potentially leading to imbalances impacting the overall health
and well-being of animals and humans (56). However, the precise
mechanisms by which mycotoxins elicit these effects remain un-
clear. Further studies using molecular approaches, such as high-
throughput mRNA sequencing and proteomics, will be useful to
elucidate themechanistic pathways involved in understanding the
dynamic interplay that occurs between Fusarium toxins and IECs
(57).
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